KMT2A‐MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8‐year follow‐up-Reference-Cited by-同舟云学术

KMT2A‐MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8‐year follow‐up

Published:2021-09-22 Issue:1 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Felix Carolyn A.¹²^ORCID,Slater Diana J.¹³⁴,Davenport James W.¹,Yu Xiang⁵^ORCID,Gregory Brian D.⁵^ORCID,Li Marilyn M.²⁶⁷⁸,Rappaport Eric F.³,Cheung Nai‐Kong V.⁹^ORCID

Affiliation:

1. Division of Oncology, The Children's Hospital of Philadelphia Center for Childhood Cancer Research Philadelphia Pennsylvania 19104

2. Department of Pediatrics Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania 19104

3. Nucleic Acids and PCR Core Facility The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104

4. Current Affiliations: D.J.S., Center for Applied Genomics The Children's Hospital of Philadelphia; X.Y., School of Life Science and Biotechnology Shanghai Jiao Tong University Shanghai China

5. Biology Department University of Pennsylvania Philadelphia Pennsylvania 19104

6. Department of Pathology and Laboratory Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania 19104

7. Division of Genomic Diagnostics Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104

8. Department of Pathology and Laboratory Medicine The Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104

9. Department of Pediatrics Memorial Sloan Kettering Cancer Center New York New York 10021

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29344

Reference49 articles.

1. A safer regimen for high-risk neuroblastoma

2. In Reply:

3. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review.

4. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

5. Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rearrangement of KMT2A Characterizes a Subset of Pediatric Parotid Mucoepidermoid Carcinomas Arising Metachronous to Acute Lymphoblastic Leukemia;Fetal and Pediatric Pathology;2023-07-30